Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

Gerinda Therapeutics Inc
Profile last edited on: 9/13/13      CAGE: 55E74      UEI:

Business Identifier: drugs for the treatment of Acute Myeloid Leukemia (AML) and other cancers.
Year Founded
2008
First Award
2012
Latest Award
2012
Program Status
Inactive
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

10001 Sheldon Drive
Cary, NC 27513
   (858) 336-8273
   N/A
   N/A
Location: Single
Congr. District: 04
County: Wake

Public Profile

Gerinda Therapeutics develops targeted drugs for the treatment of Acute Myeloid Leukemia (AML) and other cancers.

Extent of SBIR involvement

User Avatar
Phase I Awards
1
Phase II Awards
0
Conversion Rate
0.00%
Phase I Dollars
$248,481
Phase II Dollars
$0
Total Awarded
$248,481

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
Less than .5M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
2012 1 NIH $248,481
Project Title: New Ultra-Selective Kinase Inhibitors For The Treatment Of Aml

Key People / Management

  Magnus Pfahl -- CEO

  BHASKAR VENEPALLI

Company News

There are no news available.